vs
Avantor, Inc.（AVTR）与CoStar Group（CSGP）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是CoStar Group的1.8倍（$1.7B vs $899.9M），CoStar Group净利率更高（5.2% vs 3.1%，领先2.0%），CoStar Group同比增速更快（26.9% vs -1.4%），Avantor, Inc.自由现金流更多（$117.2M vs $101.3M），过去两年CoStar Group的营收复合增速更高（17.1% vs -0.5%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
CoStar Group是1987年成立的美国商业地产服务商，总部位于弗吉尼亚州阿灵顿，业务覆盖北美、欧洲地区，为商业地产行业提供信息、分析及营销解决方案，旗下运营CoStar线上数据库、新闻网站及Apartments.com、Homes.com等多个线上平台。
AVTR vs CSGP — 直观对比
营收规模更大
AVTR
是对方的1.8倍
$899.9M
营收增速更快
CSGP
高出28.2%
-1.4%
净利率更高
CSGP
高出2.0%
3.1%
自由现金流更多
AVTR
多$15.9M
$101.3M
两年增速更快
CSGP
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $899.9M |
| 净利润 | $52.4M | $46.5M |
| 毛利率 | 31.5% | 78.6% |
| 营业利润率 | 7.6% | 5.5% |
| 净利率 | 3.1% | 5.2% |
| 营收同比 | -1.4% | 26.9% |
| 净利润同比 | -89.5% | -22.2% |
| 每股收益（稀释后） | $0.08 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRCSGP
| Q4 25 | $1.7B | $899.9M | ||
| Q3 25 | $1.6B | $833.6M | ||
| Q2 25 | $1.7B | $781.3M | ||
| Q1 25 | $1.6B | $732.2M | ||
| Q4 24 | $1.7B | $709.4M | ||
| Q3 24 | $1.7B | $692.6M | ||
| Q2 24 | $1.7B | $677.8M | ||
| Q1 24 | $1.7B | $656.4M |
净利润AVTRCSGP
| Q4 25 | $52.4M | $46.5M | ||
| Q3 25 | $-711.8M | $-30.9M | ||
| Q2 25 | $64.7M | $6.2M | ||
| Q1 25 | $64.5M | $-14.8M | ||
| Q4 24 | $500.4M | $59.8M | ||
| Q3 24 | $57.8M | $53.0M | ||
| Q2 24 | $92.9M | $19.2M | ||
| Q1 24 | $60.4M | $6.7M |
毛利率AVTRCSGP
| Q4 25 | 31.5% | 78.6% | ||
| Q3 25 | 32.4% | 79.3% | ||
| Q2 25 | 32.9% | 78.5% | ||
| Q1 25 | 33.8% | 79.1% | ||
| Q4 24 | 33.4% | 80.1% | ||
| Q3 24 | 32.9% | 79.7% | ||
| Q2 24 | 34.1% | 80.0% | ||
| Q1 24 | 34.0% | 78.5% |
营业利润率AVTRCSGP
| Q4 25 | 7.6% | 5.5% | ||
| Q3 25 | -40.0% | -6.1% | ||
| Q2 25 | 7.7% | -3.5% | ||
| Q1 25 | 9.3% | -5.8% | ||
| Q4 24 | 37.8% | 5.6% | ||
| Q3 24 | 7.3% | 3.4% | ||
| Q2 24 | 10.3% | -2.4% | ||
| Q1 24 | 8.7% | -6.5% |
净利率AVTRCSGP
| Q4 25 | 3.1% | 5.2% | ||
| Q3 25 | -43.8% | -3.7% | ||
| Q2 25 | 3.8% | 0.8% | ||
| Q1 25 | 4.1% | -2.0% | ||
| Q4 24 | 29.7% | 8.4% | ||
| Q3 24 | 3.4% | 7.7% | ||
| Q2 24 | 5.5% | 2.8% | ||
| Q1 24 | 3.6% | 1.0% |
每股收益（稀释后）AVTRCSGP
| Q4 25 | $0.08 | $0.12 | ||
| Q3 25 | $-1.04 | $-0.07 | ||
| Q2 25 | $0.09 | $0.01 | ||
| Q1 25 | $0.09 | $-0.04 | ||
| Q4 24 | $0.73 | $0.14 | ||
| Q3 24 | $0.08 | $0.13 | ||
| Q2 24 | $0.14 | $0.05 | ||
| Q1 24 | $0.09 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $1.6B |
| 总债务越低越好 | $3.9B | $140.0M |
| 股东权益账面价值 | $5.6B | $8.3B |
| 总资产 | $11.8B | $10.5B |
| 负债/权益比越低杠杆越低 | 0.71× | 0.02× |
8季度趋势，按日历期对齐
现金及短期投资AVTRCSGP
| Q4 25 | $365.4M | $1.6B | ||
| Q3 25 | $251.9M | $1.9B | ||
| Q2 25 | $449.4M | $3.6B | ||
| Q1 25 | $315.7M | $3.7B | ||
| Q4 24 | $261.9M | $4.7B | ||
| Q3 24 | $285.3M | — | ||
| Q2 24 | $272.6M | — | ||
| Q1 24 | $234.9M | — |
总债务AVTRCSGP
| Q4 25 | $3.9B | $140.0M | ||
| Q3 25 | $3.9B | $1.0B | ||
| Q2 25 | $4.2B | $1.0B | ||
| Q1 25 | $4.1B | $1.0B | ||
| Q4 24 | $4.1B | $1.0B | ||
| Q3 24 | $4.9B | $1.0B | ||
| Q2 24 | $5.1B | $1.0B | ||
| Q1 24 | $5.3B | $1.0B |
股东权益AVTRCSGP
| Q4 25 | $5.6B | $8.3B | ||
| Q3 25 | $5.6B | $8.6B | ||
| Q2 25 | $6.3B | $8.6B | ||
| Q1 25 | $6.1B | $8.6B | ||
| Q4 24 | $6.0B | $7.6B | ||
| Q3 24 | $5.6B | $7.5B | ||
| Q2 24 | $5.4B | $7.4B | ||
| Q1 24 | $5.3B | $7.3B |
总资产AVTRCSGP
| Q4 25 | $11.8B | $10.5B | ||
| Q3 25 | $11.7B | $10.8B | ||
| Q2 25 | $12.8B | $10.5B | ||
| Q1 25 | $12.3B | $10.4B | ||
| Q4 24 | $12.1B | $9.3B | ||
| Q3 24 | $12.8B | $9.1B | ||
| Q2 24 | $12.7B | $9.1B | ||
| Q1 24 | $12.8B | $9.0B |
负债/权益比AVTRCSGP
| Q4 25 | 0.71× | 0.02× | ||
| Q3 25 | 0.69× | 0.12× | ||
| Q2 25 | 0.67× | 0.12× | ||
| Q1 25 | 0.67× | 0.12× | ||
| Q4 24 | 0.68× | 0.13× | ||
| Q3 24 | 0.89× | 0.13× | ||
| Q2 24 | 0.94× | 0.14× | ||
| Q1 24 | 1.00× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $162.1M |
| 自由现金流经营现金流 - 资本支出 | $117.2M | $101.3M |
| 自由现金流率自由现金流/营收 | 7.0% | 11.3% |
| 资本支出强度资本支出/营收 | 2.1% | 6.8% |
| 现金转化率经营现金流/净利润 | 2.91× | 3.49× |
| 过去12个月自由现金流最近4个季度 | $495.0M | $123.0M |
8季度趋势，按日历期对齐
经营现金流AVTRCSGP
| Q4 25 | $152.7M | $162.1M | ||
| Q3 25 | $207.4M | $68.2M | ||
| Q2 25 | $154.4M | $146.5M | ||
| Q1 25 | $109.3M | $53.2M | ||
| Q4 24 | $173.3M | $94.6M | ||
| Q3 24 | $244.8M | $100.3M | ||
| Q2 24 | $281.1M | $58.1M | ||
| Q1 24 | $141.6M | $139.6M |
自由现金流AVTRCSGP
| Q4 25 | $117.2M | $101.3M | ||
| Q3 25 | $171.7M | $-5.5M | ||
| Q2 25 | $124.8M | $27.7M | ||
| Q1 25 | $81.3M | $-500.0K | ||
| Q4 24 | $145.8M | $25.2M | ||
| Q3 24 | $204.0M | $40.2M | ||
| Q2 24 | $235.3M | $-14.7M | ||
| Q1 24 | $106.9M | $-237.1M |
自由现金流率AVTRCSGP
| Q4 25 | 7.0% | 11.3% | ||
| Q3 25 | 10.6% | -0.7% | ||
| Q2 25 | 7.4% | 3.5% | ||
| Q1 25 | 5.1% | -0.1% | ||
| Q4 24 | 8.6% | 3.6% | ||
| Q3 24 | 11.9% | 5.8% | ||
| Q2 24 | 13.8% | -2.2% | ||
| Q1 24 | 6.4% | -36.1% |
资本支出强度AVTRCSGP
| Q4 25 | 2.1% | 6.8% | ||
| Q3 25 | 2.2% | 8.8% | ||
| Q2 25 | 1.8% | 15.2% | ||
| Q1 25 | 1.8% | 7.3% | ||
| Q4 24 | 1.6% | 9.8% | ||
| Q3 24 | 2.4% | 8.7% | ||
| Q2 24 | 2.7% | 10.7% | ||
| Q1 24 | 2.1% | 57.4% |
现金转化率AVTRCSGP
| Q4 25 | 2.91× | 3.49× | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.39× | 23.63× | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 0.35× | 1.58× | ||
| Q3 24 | 4.24× | 1.89× | ||
| Q2 24 | 3.03× | 3.03× | ||
| Q1 24 | 2.34× | 20.84× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
CSGP
| Co Star | $503.8M | 56% |
| Other | $283.0M | 31% |
| Loop Net | $94.7M | 11% |
